Wedbush Research

Wedbush Morning Call - Jun 06 2019 1:23AM

Alphabet Class A

Alphabet is a holding company. The company has two segments: Google and Other Bets. Google includes the company's main products such as Ads, Android, Chrome, Google Cloud, Google Maps, Google Play, Hardware (including Nest), Search, and YouTube. The company provides a range of products across screens and formats. Also, the company delivers both performance advertising and brand advertising. Other Bets includes businesses such as Access, Calico, CapitalG, GV, Verily, Waymo, and X. Other Bets primarily engages in the sale of internet and TV services through Access as well as licensing and research and development services through Verily. Inc. serves consumers through its online and physical stores. The company also manufactures and sells electronic devices, including Kindle e-readers, Fire tablets, Fire TVs, and Echo devices, and the company develops and produces media content. The company provides programs that enable sellers to grow their businesses, sell their products in its stores, and fulfill orders through the company The company serves developers and enterprises of various sizes, including start-ups, government agencies, and academic institutions, through its Amazon Web Services segment, which provides a set of global compute, storage, database, and other service offerings. In addition, the company provides services, such as advertising.

American Eagle Outfitters Inc.

American Eagle Outfitters is a multi-brand retailer. The company operates retail stores and online at and The company provides a range of apparel and accessories for men and women under the American Eagle Outfitters brand, and intimates, apparel and personal care products for women under the Aerie brand. The company operates stores in the U.S., Canada, Mexico, Hong Kong, and China. The company also has license agreements with third-parties to operate American Eagle Outfitters and Aerie stores throughout Asia, Europe, India, Latin America and the Middle East. The company also operates two other brands, Tailgate, a vintage, sports-inspired apparel brand, and Todd Snyder New York, a menswear brand.

Anaptys Bio

AnaptysBio is a clinical stage biotechnology company developing antibody product candidates. Etokimab, the company's anti-IL-33 antibody drug candidate, inhibits the activity of the interleukin-33 cytokine that is applicable to the treatment of atopic inflammatory disorders, such as moderate-to-severe atopic dermatitis, eosinophilic asthma, chronic rhinosinusitis with nasal polyps, and potentially other allergic conditions. ANB019 inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases including generalized pustular psoriasis and palmoplantar pustulosis. The company's wholly-owned pipeline includes anti-inflammatory checkpoint receptor modulator antibodies.


Aravive is clinical-stage biotechnology company focused on developing therapies that target survival pathways for both advanced solid tumors as well as hematologic malignancies. The company's primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression. The U.S. Food and Drug Administration, designated as a Fast Track development program the investigation of the company's primary development candidate, Aravive-S6-500, for platinum-resistant recurrent ovarian cancer.

Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer immunotherapies. The company has four clinical-stage product candidates: AB928, which is an orally bioavailable, reversible antagonist of the adenosine 2a and adenosine 2b receptors; AB680, which is a reversible and selective inhibitor of the CD73 enzyme; AB122, which is a human antibody with similar binding affinity and other characteristics to the marketed anti-PD-1 antibodies pembrolizumab and nivolumab; and AB154, which is a humanized antibody that inhibits an immune checkpoint target involved in a pathway that plays both inhibitory and stimulatory roles in the immune system.

Beazer Homes USA Inc.

Beazer Homes USA is a homebuilder. The company's homebuilding operations consist of the design, sale, and construction of single-family and multi-family homes in Arizona, California, Nevada, Texas, Indiana, Maryland/Delaware, Tennessee, Virginia, Florida, Georgia, North Carolina, and South Carolina. The company acts as the general contractor for the construction of its new home communities. The company's project development activities are controlled by its operating divisions whose employees supervise the construction of each new home community by coordinating the activities of subcontractors and suppliers, subjecting their work to quality and cost controls and ensuring compliance with zoning and building codes.

BJ's Restaurants Inc.

BJ's Restaurants operates in the casual dining segment of the restaurant industry. The company's restaurants feature a number of menu offerings including: slow roasted entrees, such as, prime rib; EnLIGHTened Entrees? such as its Cherry Chipotle Glazed Salmon; its deep-dish pizza; the Pizookie? dessert; and its BJ's proprietary craft beers. The company owns and operates restaurants located in various states, and its proprietary craft beer is produced at various locations, its Temple, TX brewpub locations and by independent third party brewers using its proprietary recipes. The company also produces its proprietary non-alcoholic craft sodas including root beer, ginger beer, cream, orange and black cherry soda.

Blueprint Medicines

Blueprint Medicines is a therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy. The company's drug candidates are: avapritinib, which targets KIT and PDGFRa mutations; BLU-667, which targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or fusions; BLU-554, which targets FGFR4, a kinase that is aberrantly activated in a defined subset of patients with hepatocellular carcinoma, the common type of liver cancer; and BLU-782, which is for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the activin-like kinase 2 gene, ACVR1.

Century Communities

Century Communities is engaged in the development, design, construction, marketing and sale of single-family attached and detached homes in the States of Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Nevada, North Carolina, Ohio, South Carolina, Tennessee, Texas, Utah, and Washington. In several of the company's projects, in addition to building homes, the company is responsible for the entitlement and development of the underlying land. The company builds and sells homes under its Century Communities and Wade Jurney Homes brands. The company's homebuilding operations are organized into the following five reportable segments: West, Mountain, Texas, Southeast, and Wade Jurney Homes.


Cloudera is the enterprise data cloud company. The company's portable, multi-cloud platform with common security, governance and data management functions supports products that include streaming analytics at the edge, data engineering, data warehousing, real-time operational analytics, exploratory data science and machine learning offerings. The company primarily provides subscriptions for the following five editions of its software platform including: Cloudera Enterprise Data Hub, Cloudera Data Warehouse, Cloudera Data Science and Engineering, Cloudera Operational DB, Cloudera DataFlow, Hortonworks Data Platform and Cloudera Data Science Workbench.

CytomX Therapeutics

CytomX Therapeutics is clinical-stage, oncology-focused biopharmaceutical company with a class of investigational antibody therapeutics based on its Probody? technology platform the treatment of cancer. The company uses its platform to create proprietary cancer immunotherapies against clinically-validated targets. The company's two programs, CX-072, a wholly owned PD-L1-targeting Probody therapeutic and CX-2009, wholly owned CD166-targeting Probody drug conjugate. Both CX-072 and CX-2009 are part of PROCLAIM (Probody Clinical Assessment in Man), an international umbrella clinical trial program that provides clinical trial sites with access to the company's novel therapies under one central protocol.

Epizyme Inc

Epizyme is a late-stage biopharmaceutical company that is focused on the treatment for people with cancer and other diseases through the discovery, development, and commercialization of epigenetic medicines. The company's lead product candidate, tazemetostat, is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase for the treatment of a range of cancer types in multiple treatment settings, and its G9a program, EZM8266, is used for the treatment of sickle cell disease. The company owns the global development and commercialization rights to tazemetostat outside of Japan. Eisai Co. Ltd holds the rights to develop and commercialize tazemetostat in Japan.

Five Prime Therapeutics Inc

Five Prime Therapeutics is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The company's key product candidates are: FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 that it is studying in a clinical trial in multiple cancers; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that the company is studying in a clinical trial in multiple cancers; and Cabiralizumab (FPA008) is an antibody that the company and its partner Bristol-Myers Squibb Company, or BMS, are studying in clinical trials in multiple cancers in combination with BMS's PD-1 immune checkpoint inhibitor, Opdivo? (nivolumab).

G1 Therapeutics

G1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company's product pipeline includes three clinical candidates: trilaciclib, a short-acting intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that preserves hematopoietic stem and progenitor cells and immune system function; lerociclib, an oral CDK4/6 inhibitor that inhibits tumor proliferation and growth; and G1T48, an oral selective estrogen receptor degrader that inhibits estrogen receptor driven tumor proliferation.

Gap Inc.

The Gap is an apparel retail company. The company provides apparel, accessories, and personal care products for men, women, and children under the Old Navy, Gap, Banana Republic, Athleta, Intermix, and Hill City brands. The company has stores in the U.S., Canada, the U.K., France, Ireland, Japan, Italy, China, Hong Kong, Taiwan, and Mexico, and has franchise agreements with unaffiliated franchisees to operate Old Navy, Gap, and Banana Republic stores throughout Asia, Europe, Latin America, the Middle East, and Africa. Under these agreements, third parties operate stores that sell apparel and related products under the company's brand names.

Karyopharm Therapeutics

Karyopharm Therapeutics is a clinical-stage pharmaceutical company. The company is focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has discovered and is developing small molecule Selective Inhibitors of Nuclear Export (SINE), compounds that inhibit the nuclear export protein (XPO1). The company's SINE compounds were the first oral XPO1 inhibitors in clinical development. The company's focus is on seeking the commercialization of its primary drug candidate, selinexor (KPT-330), as an oral agent in cancer indications with clinical need, initially for hematologic malignancies.

L Brands

L Brands is a holding company. Through its subsidiaries, the company is a specialty retailer of women's intimate and other apparel, personal care, beauty and home fragrance products. The company sells its merchandise through company-owned specialty retail stores in the U.S., Canada, the U.K., Ireland and Greater China, and through its websites and other channels. The company's other international operations are primarily through franchise, license and wholesale partners. The company has three reportable segments: Victoria's Secret, Bath & Body Works and Victoria's Secret and Bath & Body Works International. The company operates the following retail brands: Victoria's Secret, PINK and Bath & Body Works.


MacroGenics discovers and develops antibody-based therapeutics to modulate the human immune response for the treatment of cancer. The company has a pipeline of product candidates in human clinical testing, including immuno-oncology programs, that have been created using its proprietary antibody-based technology platforms. The company is developing product candidates that target various tumor-associated antigens, including HER2. The company is also developing a franchise of molecules that target programmed cell death protein 1 (PD-1). The company is developing two bispecific DART product candidates that engage PD-1 and lymphocyte-activation gene 3, as well as PD-1 and cytotoxic T-lymphocyte-associated protein 4.

Mersana Therapeutics

Mersana Therapeutics is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADCs) for cancer patients. The company's primary product candidate, XMT-1536, is an ADC targeting NaPi2b, an antigen broadly expressed in ovarian cancer and non small cell lung cancer. In addition, the company has established research and development partnerships with Merck KGaA and Asana Biosciences for the development and commercialization of additional ADC product candidates against a limited number of targets selected by the company's partners based on its Dolaflexin platform.

Microsoft Corp.

Microsoft is a technology company. The company develops and supports software, services, devices, and solutions. The company provides an array of services, including cloud-based solutions as well as solution support and consulting services. The company also delivers relevant online advertising. The company's products include operating systems; cross-device productivity applications; server applications; business solution applications; desktop and server management tools; software development tools; and video games. The company also designs, manufactures, and sells devices, including personal computers, tablets, gaming and entertainment consoles, other devices, and related accessories.

Oracle Corp.

Oracle provides products and services that address enterprise information technology (IT) environments. The company's products and services include applications and infrastructure offerings. The company's cloud and license business engages in the sale, marketing and delivery of its applications and infrastructure technologies through cloud and on-premise deployment models including its cloud services and license support offerings; and its cloud license and on-premise license offerings. The company's hardware business provides Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management and other hardware-related software to support diverse IT environments.

Replimune Group

Replimune Group is a clinical-stage biotechnology company focused on the development of oncolytic immunotherapies to treat cancer. The company's primary product candidate, RP1, is a selectively replicating version of herpes simplex virus 1 that expresses GALV-GP R(-) and human GM-CSF. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4, a protein that inhibits the immune response to tumors. The company has designed its RP3 product candidate to express immune-activating proteins that stimulate T cells, in addition to anti-CTLA-4 and GALV-GP R(-).

Sierra Oncology

Sierra Oncology is a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. The company's primary drug candidate, momelotinib, which is for the treatment of myelofibrosis. The company is also advancing, SRA737, is a selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a main regulator of cell cycle progression and the DNA Damage Response replication stress response. The company's pipeline also includes SRA141, a selective, orally bioavailable small molecule inhibitor of cell division cycle 7 kinase.

Stemline Therapeutics Inc

Stemline Therapeutics is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The company's product, ELZONRIS? (tagraxofusp-erzs; SL-401) has been approved by the U.S. Food and Drug Administration for the treatment of blastic plasmacytoid dendritic cell neoplasm in adult and pediatric patients two years and older. The company's pipeline of product candidates includes: SL-801 for patients with solid tumors; SL-701, an immunotherapeutic, which has completed a Phase 2 trial in patients with second-line glioblastoma; and SL-901, an oral, small molecule kinase inhibitor, assessed in Phase 1 trial of patients with solid tumors.

Sutro Biopharma

Sutro Biopharma is a clinical stage drug discovery, development and manufacturing company. The company focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.

TCR2 Therapeutics

Urban Jakarta Propertindo

Urban Jakarta Propertindo Tbk PT Formerly known as Urban Jakarta Propertindo PT. PT Urban Jakarta Propertindo Tbk is an Indonesia based company primarily engaged in property development and management.

Willdan Group

Willdan Group is a holding company. Through its subsidiaries, the company is a provider of technical and consulting services to utilities, private industry, and public agencies of government. The company provides services in two segments: Energy, which services include surveys, program design, master planning, benchmarking analyses, design engineering, construction management, performance contracting, installation, alternative financing, and measurement and verification services; and Engineering and Consulting, which provides civil engineering-related construction management, building and safety, city engineering, city planning, geotechnical, and other engineering consulting services to the company's clients.


Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat diseases with unmet medical needs. The company is developing a suite of clinical-stage drug candidates from its proprietary XmAb? technology platforms that are designed to treat cancer, autoimmune and allergic diseases, and other conditions. The company's protein engineering efforts and the XmAb technologies are focused on the portion of the antibody that interacts with multiple segments of the immune system and controls antibody structure. This portion, referred to as the Fc domain, is constant and interchangeable among antibodies.


Since our founding in 1955, Wedbush has been a leader in the financial industry providing our clients with a wide range of services; including institutional sales, correspondent clearing services, equity research, corporate and municipal finance, equity market making, fixed income trading, prime brokerage, and wealth management. Headquartered in Los Angeles, with 100 registered offices, the firm focuses on dedicated service, client financial safety, continuity, and advanced technology.

Wedbush Research

Other Reports on these Companies
Other Reports from Wedbush
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch